CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc.

马萨诸塞州剑桥市，2024年6月5日（环球通讯社）--Relay Therapeutics，Inc.（纳斯达克：RLAY），一家临床阶段的精准医学公司，通过结合前沿计算和实验技术来改变药物发现过程，今天宣布与辉瑞公司进行临床试验合作。

(NYSE: PFE) to evaluate atirmociclib, Pfizer’s investigative selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer. “We are very enthusiastic to evaluate Pfizer's novel investigative selective-CDK4 inhibitor atirmociclib in combination with RLY-2608, the first mutant selective PI3Kα inhibitor,” said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics.

（纽约证券交易所：PFE）评估辉瑞公司的研究性选择性CDK4抑制剂阿曲莫西利联合RLY-2608和氟维司群治疗PI3Kα突变，HR+，HER2转移性乳腺癌患者。Relay Therapeutics研发总裁Don Bergstrom医学博士说：“我们非常热衷于评估辉瑞公司的新型研究性选择性CDK4抑制剂atirmociclib与第一种突变选择性PI3Kα抑制剂RLY-2608的组合。”。

“We believe that combining these two selective agents – atirmociclib and RLY-2608 – will avoid key off-target toxicity that comes from hitting CDK6 and wild-type PI3Kα, which has historically significantly limited use of non-selective agents. The breast cancer treatment landscape continues to evolve quickly, and we are pleased that the safety profile RLY-2608 has demonstrated to-date makes it well-positioned to be part of the next generation of therapies.” Under the terms of the agreement, Pfizer will provide atirmociclib for use in the study and Relay will be responsible for conducting the study.

“我们相信，将这两种选择性药物-阿替莫西利和RLY-2608-结合使用，可以避免因打击CDK6和野生型PI3Kα而产生的关键脱靶毒性，而野生型PI3Kα在历史上一直严重限制非选择性药物的使用。乳腺癌治疗领域继续快速发展，我们很高兴迄今为止，RLY-2608的安全性已证明它能够很好地成为下一代疗法的一部分。”根据协议条款，辉瑞将提供阿替莫西利用于研究，Relay将负责进行这项研究。

The RLY-2608 + atirmociclib + fulvestrant triplet combination is planned to begin by the end of 2024. About RLY-2608 RLY-2608 is the lead program in Relay Therapeutics’ efforts to discover and develop mutant selective inhibitors of PI3Kα, the most frequently mutated kinase in all cancers, with oncogenic mutations detected in about 14% of patients with solid tumors.

RLY-2608+atirmociclib+氟维司群三联体组合计划于2024年底开始。关于RLY-2608 RLY-2608是Relay Therapeutics努力发现和开发PI3Kα突变选择性抑制剂的主要项目，PI3Kα是所有癌症中突变频率最高的激酶，在约14%的实体瘤患者中检测到致癌突变。

RLY-2608 has the potential, if approved, to address more t.

如果获得批准，RLY-2608有可能解决更多的t。